| P50 | author | Eduardo L. Franco | Q39669535 |
| P2093 | author name string | Alex Ferenczy | |
| P2860 | cites work | Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000 | Q22306086 |
| | Predictors of STI vaccine acceptability among parents and their adolescent children | Q39727288 |
| | Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. | Q40450678 |
| | Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities | Q44113435 |
| | A controlled trial of a human papillomavirus type 16 vaccine | Q44366335 |
| | Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage | Q44889298 |
| | Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine | Q45404942 |
| | Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 |
| | Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis | Q46926059 |
| | Determinants of cervical cancer rates in developing countries | Q47436981 |
| | Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. | Q50723929 |
| | The health care costs of cervical human papillomavirus--related disease. | Q50747240 |
| | The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. | Q51968734 |
| | The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). | Q54570190 |
| | The Role of Human Papillomaviruses in Cancer | Q57089422 |
| | Parental acceptance of the human papillomavirus vaccine | Q57245515 |
| | Overview of the European and North American studies on HPV testing in primary cervical cancer screening | Q57414808 |
| | Cervical Coinfection with Human Papillomavirus (HPV) Types and Possible Implications for the Prevention of Cervical Cancer by HPV Vaccines | Q58053669 |
| | Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 |
| | Condom use and the risk of genital human papillomavirus infection in young women | Q28247581 |
| | Against which human papillomavirus types shall we vaccinate and screen? The international perspective | Q28267023 |
| | The global health burden of infection-associated cancers in the year 2002 | Q28290871 |
| | Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 |
| | Classification of papillomaviruses | Q29618731 |
| | Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada | Q31030012 |
| | Treatment for cervical intraepithelial neoplasia and risk of preterm delivery | Q31057677 |
| | Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. | Q34279292 |
| | Role of herd immunity in determining the effect of vaccines against sexually transmitted disease | Q34380787 |
| | Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial | Q34415030 |
| | Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only | Q34568949 |
| | American Cancer Society guideline for the early detection of cervical neoplasia and cancer | Q35018624 |
| | A review of human papillomavirus vaccines from basic science to clinical trials | Q35109351 |
| | A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine | Q35199478 |
| | How will HPV vaccines affect cervical cancer? | Q35235035 |
| | Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population | Q35932976 |
| | Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control | Q36065397 |
| | Vaccination as a prevention strategy for human papillomavirus-related diseases | Q36323240 |
| | Worldwide burden of gynaecological cancer: the size of the problem | Q36344510 |
| | Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review | Q36368845 |
| | Advances in prevention of cervical cancer and other human papillomavirus-related diseases | Q36389268 |
| | ACOG Committee Opinion. Evaluation and management of abnormal cervical cytology and histology in the adolescent. Number 330, April 2006. | Q36438420 |
| | Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). | Q36530204 |
| | Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination | Q36537615 |
| | Chapter 5: Updating the natural history of HPV and anogenital cancer | Q36584420 |
| | Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists | Q36595677 |
| | Flat penile lesions: the infectious "invisible" link in the transmission of human papillomavirus | Q36599988 |
| | Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland | Q36609838 |
| | Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK | Q36610489 |
| | High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up | Q36612475 |
| | Prospects for cervical cancer prevention by human papillomavirus vaccination | Q36641811 |
| | HPV DNA testing for cervical cancer screening. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer | Q36679727 |
| P433 | issue | 4 | |
| P921 | main subject | HPV vaccine | Q900189 |
| P304 | page(s) | 511-525 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Prophylactic human papillomavirus vaccines: potential for sea change | |
| P478 | volume | 6 | |